Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Nephrology

Does adjunctive CytoSorb therapy improve inflammatory indices in crush syndrome patients receiving continuous renal replacement therapy? A retrospective cohort study

  1. 1Department of Orthopaedics and Traumatology, Basaksehir Cam ve Sakura City Hospital, Olimpiyat Bulvarı, Başakşehir, Istanbul, 34480 Turkey
  2. 2Department of Nephrology and Organ Transplantation Unit, Basaksehir Cam ve Sakura City Hospital, Olimpiyat Bulvarı, Başakşehir, Istanbul, 34480 Turkey

Abstract

Background: Cytokine adsorption therapy has gained increasing interest as an adjunct to continuous renal replacement therapy (CRRT) in critically ill patients with excessive systemic inflammation. However, whether its addition to CRRT effectively reduces systemic inflammatory burden remains unclear. Complete blood count (CBC) - derived inflammatory indices may provide practical information on the magnitude of systemic inflammation when direct cytokine measurements are not readily available. This study aimed to investigate whether the addition of a cytokine-adsorbing filter to CRRT was associated with measurable differences in CBC-derived inflammatory indices among patients with crush syndrome following the February 6, 2023, Kahramanmaraş earthquakes.

Methods: This retrospective cohort study included 22 adult patients with crush syndrome treated at a tertiary trauma center following the February 6, 2023, Kahramanmaraş earthquakes. Patients were categorized into three groups: CRRT alone (n = 8), CRRT with cytokine adsorption membrane (n = 10), and no CRRT (n = 4). Blood cell derived inflammatory indices including; neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune–inflammation index, systemic inflammation response index, aggregate index of systemic inflammation, and C-reactive protein-to-albumin ratio, were calculated as baseline (Day 0) and 72 h later (Day 3). Day 3 values and changes from Day 0 to Day 3 were compared among the groups using the Kruskal–Wallis test. For PLR, CRP, and absolute blood cell counts, analyses of covariance were additionally performed to compare Day 3 values among the groups after adjustment for the corresponding baseline values, where model assumptions were satisfied.

Results: No statistically significant differences were observed among the groups in the selected baseline demographic, clinical, and laboratory variables. Among the investigated inflammatory indices, only Day 3 PLR and its absolute 72-hour change differed significantly among the groups. After adjustment for baseline PLR, Day 3 PLR remained significantly different among the treatment groups (F(2,17) = 11.189, p < 0.001, partial η²=0.568). Bonferroni-adjusted comparisons showed lower adjusted Day 3 PLR in the CRRT plus CytoSorb group than in the CRRT-only group (p = 0.017) and the no-CRRT group (p = 0.001), whereas the CRRT-only and no-CRRT groups did not differ significantly (p = 0.339). No significant between-group differences were observed for the other inflammatory indices.

Conclusions: In this small retrospective cohort, adjunctive CytoSorb® hemoadsorption during CRRT was not associated with a consistent additional improvement across most routine laboratory-derived inflammatory indices compared with CRRT alone. However, after adjustment for baseline values, Day 3 PLR was significantly lower in the CRRT plus CytoSorb group than in the CRRT-only group. Given the limited sample size, non-random treatment allocation, indirect nature of PLR, and absence of direct cytokine measurements, this finding should be regarded as exploratory and hypothesis-generating rather than as evidence of a specific cytokine-removal or clinical treatment effect.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05280-7.

Related

  1. Adjunctive effects of acupuncture and moxibustion in women with premature ovarian insufficiency receiving hormone replacement therapy: protocol for a multicenter, assessor-blinded, 2 × 2 factorial randomized controlled trial
    Chunxia Lu, Tingting Ye, Jin Cui +1
    Frontiers in EndocrinologyPeer-reviewedCC BY 4.0Full textEndocrinology & metabolismCrossrefEurope PMCPMCEurope PMC
  2. Cytokine and Vasopressor Trajectories During Continuous Renal Replacement Therapy with oXiris, CytoSorb, or Standard Haemofilters in Sepsis-Associated Acute Kidney Injury: An Exploratory Retrospective Cohort Study
    Tamara Mirela Porosnicu, Ciprian Gindac, Ahmed Elagez +6
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Association of Preoperative Plateletcrit and Other Inflammatory Indices with Postoperative Pain Severity and Opioid Consumption in Morbidly Obese Patients Receiving Transversus Abdominis Plane Block: A Retrospective Observational Study
    Mesut Oterkus, Ümit Karatepe, Hacı Osman Toplu +1
    MetabolitesPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefEurope PMC
  4. Systemic inflammatory response index as an independent predictor of all-cause mortality in patients receiving maintenance hemodialysis: a retrospective cohort study
    Emel Tatlı, Betül Çavuşoğlu Türker, Süleyman Tuna Yolcu +5
    Frontiers in MedicinePeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  5. Comparison between regional citrate anticoagulation and systemic heparin anticoagulation in patients undergoing continuous renal replacement therapy and venoarterial extracorporeal membrane oxygenation: A retrospective multicentric study
    Axel Hirwe, Edris Omar, Pierre-Grégoire Guinot +9
    Annals of Intensive CarePeer-reviewedCC BY-NC-ND2 citedGeneral biologyGeneral medicineHAL
BibTeX
@article{civan2026does,
  title = {{Does adjunctive CytoSorb therapy improve inflammatory indices in crush syndrome patients receiving continuous renal replacement therapy? A retrospective cohort study}},
  author = {Melih Civan and Gürsel Yıldız and Mehmet Ali Talmaç},
  journal = {BMC Nephrology},
  year = {2026},
  month = aug,
  doi = {10.1186/s12882-026-05280-7},
  url = {https://doi.org/10.1186/s12882-026-05280-7},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Does adjunctive CytoSorb therapy improve inflammatory indices in crush syndrome patients receiving continuous renal replacement therapy? A retrospective cohort study
AU  - Melih Civan
AU  - Gürsel Yıldız
AU  - Mehmet Ali Talmaç
PY  - 2026
DA  - 2026/08/17
JO  - BMC Nephrology
DO  - 10.1186/s12882-026-05280-7
UR  - https://doi.org/10.1186/s12882-026-05280-7
AB  - Background: Cytokine adsorption therapy has gained increasing interest as an adjunct to continuous renal replacement therapy (CRRT) in critically ill patients with excessive systemic inflammation. However, whether its addition to CRRT effectively reduces systemic inflammatory burden remains unclear. Complete blood count (CBC) - derived inflammatory indices may provide practical information on the magnitude of systemic inflammation when direct cytokine measurements are not readily available. This study aimed to investigate whether the addition of a cytokine-adsorbing filter to CRRT was associated with measurable differences in CBC-derived inflammatory indices among patients with crush syndrome following the February 6, 2023, Kahramanmaraş earthquakes.  Methods: This retrospective cohort study included 22 adult patients with crush syndrome treated at a tertiary trauma center following the February 6, 2023, Kahramanmaraş earthquakes. Patients were categorized into three groups: CRRT alone (n = 8), CRRT with cytokine adsorption membrane (n = 10), and no CRRT (n = 4). Blood cell derived inflammatory indices including; neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune–inflammation index, systemic inflammation response index, aggregate index of systemic inflammation, and C-reactive protein-to-albumin ratio, were calculated as baseline (Day 0) and 72 h later (Day 3). Day 3 values and changes from Day 0 to Day 3 were compared among the groups using the Kruskal–Wallis test. For PLR, CRP, and absolute blood cell counts, analyses of covariance were additionally performed to compare Day 3 values among the groups after adjustment for the corresponding baseline values, where model assumptions were satisfied.  Results: No statistically significant differences were observed among the groups in the selected baseline demographic, clinical, and laboratory variables. Among the investigated inflammatory indices, only Day 3 PLR and its absolute 72-hour change differed significantly among the groups. After adjustment for baseline PLR, Day 3 PLR remained significantly different among the treatment groups (F(2,17) = 11.189, p < 0.001, partial η²=0.568). Bonferroni-adjusted comparisons showed lower adjusted Day 3 PLR in the CRRT plus CytoSorb group than in the CRRT-only group (p = 0.017) and the no-CRRT group (p = 0.001), whereas the CRRT-only and no-CRRT groups did not differ significantly (p = 0.339). No significant between-group differences were observed for the other inflammatory indices.  Conclusions: In this small retrospective cohort, adjunctive CytoSorb® hemoadsorption during CRRT was not associated with a consistent additional improvement across most routine laboratory-derived inflammatory indices compared with CRRT alone. However, after adjustment for baseline values, Day 3 PLR was significantly lower in the CRRT plus CytoSorb group than in the CRRT-only group. Given the limited sample size, non-random treatment allocation, indirect nature of PLR, and absence of direct cytokine measurements, this finding should be regarded as exploratory and hypothesis-generating rather than as evidence of a specific cytokine-removal or clinical treatment effect.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05280-7.
SN  - 1471-2369
ER  -